Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia


Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood [Internet]. 2016;128(10):1321 - 1328.


Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenström's Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durable responses and are still indicated in most patients. Approval of the BTK inhibitor ibrutinib in the United States and Europe represents a novel and effective treatment option for both treatment-naive and relapsing patients. Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising and may increase future treatment options. Active enrollment in clinical trials whenever possible was endorsed by the panel for most patients with WM. © 2016 by The American Society of Hematology.


Cited By :5Export Date: 18 February 2017References: Swerdlow, S.H., Campo, E., Harris, N.L., (2008) World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, , Lyon, France: IARC Press;Owen, R.G., Treon, S.P., Al-Katib, A., Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia (2003) Semin Oncol, 30 (2), pp. 110-115; Kyle, R.A., Treon, S.P., Alexanian, R., Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia (2003) Semin Oncol, 30 (2), pp. 116-120; Gertz, M.A., Anagnostopoulos, A., Anderson, K., Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia (2003) Semin Oncol, 30 (2), pp. 121-126; Treon, S.P., Gertz, M.A., Dimopoulos, M., Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia (2006) Blood, 107 (9), pp. 3442-3446; Dimopoulos, M.A., Gertz, M.A., Kastritis, E., Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia (2009) J Clin Oncol, 27 (1), pp. 120-126; Dimopoulos, M.A., Kastritis, E., Owen, R.G., Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus (2014) Blood, 124 (9), pp. 1404-1411; Rummel, M.J., Niederle, N., Maschmeyer, G., Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 noninferiority trial (2013) Lancet, 381 (9873), pp. 1203-1210; Buske, C., Hoster, E., Dreyling, M., The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) (2009) Leukemia, 23 (1), pp. 153-161; Buske, C., Leblond, V., How to manage Waldenstrom's macroglobulinemia (2013) Leukemia, 27 (4), pp. 762-772; Buske, C., Leblond, V., Dimopoulos, M., Kimby, E., Jäger, U., Dreyling, M., Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2013) Ann Oncol, 24, pp. vi155-vi159; Buske, C., Seymour, J.F., Immunochemotherapy in Waldenström macroglobulinemia - Still the backbone of treatment (2015) Leuk Lymphoma, 56 (9), pp. 2489-2490; Treon, S.P., How I treat Waldenström macroglobulinemia (2015) Blood, 126 (6), pp. 721-732; Treon, S.P., Agus, D.B., Link, B., CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia (2001) J Immunother, 24 (3), pp. 272-279; Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H., Greipp, P.R., Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) (2004) Leuk Lymphoma, 45 (10), pp. 2047-2055; Dimopoulos, M.A., Zervas, C., Zomas, A., Treatment of Waldenström's macroglobulinemia with rituximab (2002) J Clin Oncol, 20 (9), pp. 2327-2333; Treon, S.P., Emmanouilides, C., Kimby, E., Extended rituximab therapy in Waldenström's macroglobulinemia (2005) Ann Oncol, 16 (1), pp. 132-138; Treon, S.P., Branagan, A.R., Hunter, Z., Santos, D., Tournhilac, O., Anderson, K.C., Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia (2004) Ann Oncol, 15 (10), pp. 1481-1483; Ghobrial, I.M., Fonseca, R., Greipp, P.R., Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: An Eastern Cooperative Oncology Group Study (2004) Cancer, 101 (11), pp. 2593-2598; Wolach, O., Bairey, O., Lahav, M., Late-onset neutropenia after rituximab treatment: Case series and comprehensive review of the literature (2010) Medicine (Baltimore), 89 (5), pp. 308-318; Wolach, O., Shpilberg, O., Lahav, M., Neutropenia after rituximab treatment: New insights on a late complication (2012) Curr Opin Hematol, 19 (1), pp. 32-38; Li, S.C., Chen, Y.C., Evens, A.M., Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism (2010) Am J Hematol, 85 (10), pp. 810-812; Furman, R.R., Eradat, H., DiRienzo, C.G., A phase ii trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia (2011) Blood, 118 (21). , abstract; Castillo, J.J., Kanan, S., Meid, K., Manning, R., Hunter, Z.R., Treon, S.P., Rituximab intolerance in patients with Waldenström macroglobulinaemia Br J Haematol, , published online ahead of print November 2, 2015; Dimopoulos, M.A., Anagnostopoulos, A., Kyrtsonis, M.C., Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide (2007) J Clin Oncol, 25 (22), pp. 3344-3349; Kastritis, E., Gavriatopoulou, M., Kyrtsonis, M.C., Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: Final analysis of a phase 2 study (2015) Blood, 126 (11), pp. 1392-1394; Treon, S.P., Branagan, A.R., Ioakimidis, L., Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia (2009) Blood, 113 (16), pp. 3673-3678; Tedeschi, A., Benevolo, G., Varettoni, M., Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease (2012) Cancer, 118 (2), pp. 434-443; Tedeschi, A., Ricci, F., Goldaniga, M.C., Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia (2013) Clin Lymphoma Myeloma Leuk, 13 (2), pp. 231-234; Souchet, L., Levy, V., Ouzegdouh, M., Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia (2016) Am J Hematol, 91 (8), pp. 782-786. , FILO (French Innovative Leukemia Organization); Treon, S.P., Hanzis, C., Tripsas, C., Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia (2011) Clin Lymphoma Myeloma Leuk, 11 (1), pp. 133-135; Tedeschi, A., Picardi, P., Ferrero, S., Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia (2015) Leuk Lymphoma, 56 (9), pp. 2637-2642; Treon, S.P., Ioakimidis, L., Soumerai, J.D., Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 (2009) J Clin Oncol, 27 (23), pp. 3830-3835; Treon, S.P., Meid, K., Gustine, J., Long-term outcome of a prospective study of bortezomib, dexamethasone and rituximab (BDR) in previously untreated, symptomatic patients with Waldenstrom's macroglobulinemia (2015) Blood, 126 (23). , abstract; Ghobrial, I.M., Xie, W., Padmanabhan, S., Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia (2010) Am J Hematol, 85 (9), pp. 670-674; Ghobrial, I.M., Hong, F., Padmanabhan, S., Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia (2010) J Clin Oncol, 28 (8), pp. 1422-1428; Dimopoulos, M.A., García-Sanz, R., Gavriatopoulou, M., Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): Long-term results of a phase 2 study of the European Myeloma Network (EMN) (2013) Blood, 122 (19), pp. 3276-3282; Treon, S.P., Tripsas, C.K., Meid, K., Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia (2014) Blood, 124 (4), pp. 503-510; Treon, S.P., Hanzis, C., Manning, R.J., Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen (2011) Br J Haematol, 154 (3), pp. 357-362; Kyriakou, C., Boumendil, A., Finel, H., Autologous stem cell transplantation (ASCT) for the treatment of patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL). A risk factor analysis by the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party (2014) Blood, 124 (21). , abstract; Kyriakou, C., Canals, C., Cornelissen, J.J., Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: Report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2010) J Clin Oncol, 28 (33), pp. 4926-4934; Fouquet, G., Guidez, S., Petillon, M.O., Lenalidomide is safe and active in Waldenström macroglobulinemia (2015) Am J Hematol, 90 (11), pp. 1055-1059; Treon, S.P., Soumerai, J.D., Branagan, A.R., Lenalidomide and rituximab in Waldenstrom's macroglobulinemia (2009) Clin Cancer Res, 15 (1), pp. 355-360; Treon, S.P., Tripsas, C., Warren, D., Phase I study of pomalidomide, dexamethasone, rituximab (PDR) in patients with Waldenstrom's macroglobulinemia (2013) Proceedings of the 12th International Conference on Malignant Lymphoma, , [abstract]. June 19-22, Lugano, Switzerland; Ghobrial, I.M., Witzig, T.E., Gertz, M., Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia (2014) Am J Hematol, 89 (3), pp. 237-242; Tripsas, C.K., Meid, K., Patterson, C., Prospective, multicenter study of the mTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom's macroglobulinemia (2013) Blood, 122 (21). , abstract; Ghobrial, I.M., Redd, R., Armand, P., Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia (2015) Leukemia, 29 (12), pp. 2338-2346; Treon, S.P., Tripsas, C.K., Meid, K., Ibrutinib in previously treated Waldenström's macroglobulinemia (2015) N Engl J Med, 372 (15), pp. 1430-1440; Dimoupoulos, M.A., Trotman, J., Tedeschi, A., Ibrutinib therapy in rituximab-refractory patients with Waldenström's macroglobulinemia: Initial results from an international, multicenter, open-label phase 3 substudy (INNOVATE™) (2015) Blood, 126 (23). , abstract; Furman, R., Bilotti, E., Graef, T., Single-agent ibrutinib demonstrates long-term activity and safety in patients with relapsed/refractory Waldenstrom's macroglobulinemia (2015) Haematologica, 100 (S1), p. 705. , abstract; Levade, M., David, E., Garcia, C., Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions (2014) Blood, 124 (26), pp. 3991-3995; Hivert, B., Caron, C., Petit, S., Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia (2012) Blood, 120 (16), pp. 3214-3221; Gustine, J.N., Meid, K., Dubeau, T.E., Treon, S.P., Castillo, J.J., Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia (2016) Am J Hematol, 91 (6), pp. E312-E313; Woyach, J.A., Furman, R.R., Liu, T.M., Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib (2014) N Engl J Med, 370 (24), pp. 2286-2294; Treon, S.P., Xu, L., Hunter, Z., MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia (2015) N Engl J Med, 373 (6), pp. 584-586